Country: Evrópusambandið
Tungumál: enska
Heimild: EMA (European Medicines Agency)
canine parainfluenza virus, leptospira and rabies virus.
Zoetis Belgium S.A.
QI07AJ
canine parainfluenza virus, leptospira and rabies virus
Dogs
Immunologicals for canidae, Live and inactivated viral and bacterial vaccines
Active immunization of dogs from six weeks of age to prevent clinical signs and reduce viral excretion cause by canine parainfluenza virus, to prevent clinical signs, infection and urinary excretion cause by Leptospira serovars bratislava, canicola, grippotyphosa and icterohaemorrhagiae and to prevent mortality, clinical signs and infection cause by rabies virus.
Revision: 5
Authorised
2014-07-30
17 B. PACKAGE LEAFLET 18 PACKAGE LEAFLET: VERSICAN PLUS PI/L4R LYOPHILISATE AND SUSPENSION FOR SUSPENSION FOR INJECTION FOR DOGS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: Zoetis Belgium SA Rue Laid Burniat 1 1348 Louvain-la-Neuve BELGIUM Manufacturer responsible for batch release: Bioveta, a.s., Komenského 212, 683 23, Ivanovice na Hané, CZECH REPUBLIC 2. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus Pi/L4R lyophilisate and suspension for suspension for injection for dogs 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each dose of 1 ml contains: ACTIVE SUBSTANCES: LYOPHILISATE (LIVE ATTENUATED): MINIMUM MAXIMUM Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 10 3.1 TCID 50 * 10 5.1 TCID 50 SUSPENSION (INACTIVATED): _Leptospira interrogans_ serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 ALR** titre ≥ 1:51 _Leptospira interrogans _ serogroup Canicola _ _ serovar Canicola, strain MSLB 1090 ALR** titre ≥ 1:51 _Leptospira kirschneri _ serogroup Grippotyphosa _ _ serovar Grippotyphosa _,_ strain MSLB 1091 ALR** titre ≥ 1:40 _Leptospira interrogans _ serogroup Australis _ _ serovar Bratislava _,_ strain MSLB 1088 ALR** titre ≥ 1:51 Rabies virus, strain SAD Vnukovo-32 ≥ 2.0 IU*** ADJUVANT: Aluminium hydroxide 1.8 - 2.2 mg. * Tissue culture infectious dose 50 %. ** Antibody micro agglutination-lytic reaction. *** International units. 19 Lyophilisate: spongy matter of white colour. Suspension: pink colour with fine sediment. 4. INDICATION(S) Active immunisation of dogs from 8-9 weeks of age: − to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus, − to prevent clinical signs, infection and urinary excretion caused by _L._ _interrogans_ serogroup Australis serovar Bratislava, − to prevent clinical signs and urinary excretion and reduce infection Lestu allt skjalið
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Versican Plus Pi/L4R lyophilisate and suspension for suspension for injection for dogs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each dose of 1 ml contains: ACTIVE SUBSTANCES: LYOPHILISATE (LIVE ATTENUATED):_ _ MINIMUM MAXIMUM_ _ Canine parainfluenza Type 2 virus, strain CPiV-2 Bio 15 10 3.1 TCID 50 * 10 5.1 TCID 50 SUSPENSION (INACTIVATED): _Leptospira interrogans_ serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae strain MSLB 1089 ALR** titre ≥ 1:51 _Leptospira interrogans_ serogroup Canicola _ _ serovar Canicola, strain MSLB 1090 ALR** titre ≥ 1:51 _Leptospira kirschneri _ serogroup Grippotyphosa _ _ serovar Grippotyphosa _,_ strain MSLB 1091 ALR** titre ≥ 1:40 _Leptospira interrogans _ serogroup Australis _ _ serovar Bratislava _,_ strain MSLB 1088 ALR** titre ≥ 1:51 Rabies virus, strain SAD Vnukovo-32 ≥ 2.0 IU*** * Tissue culture infectious dose 50 %. ** Antibody micro agglutination-lytic reaction. *** International units. ADJUVANT: Aluminium hydroxide 1.8 - 2.2 mg. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Lyophilisate and suspension for suspension for injection. The visual appearance is as follows: Lyophilisate: spongy matter of white colour. Suspension: pink colour with fine sediment. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs 3 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Active immunisation of dogs from 8-9 weeks of age: − to prevent clinical signs (nasal and ocular discharge) and reduce viral excretion caused by canine parainfluenza virus, − to prevent clinical signs, infection and urinary excretion caused by _L._ _interrogans_ serogroup Australis serovar Bratislava, − to prevent clinical signs and urinary excretion and reduce infection caused by _L. interrogans_ serogroup Canicola serovar Canicola and _L. interrogans_ serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, − to prevent clinical signs and reduce infection and urinary excr Lestu allt skjalið